{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:25:55Z","timestamp":1788607555491,"version":"build-2803163510"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T00:00:00Z","timestamp":1719878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.cca.2024.119833","type":"journal-article","created":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T13:56:40Z","timestamp":1719755800000},"page":"119833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Plasma and platelet lipidome changes in Fabry disease"],"prefix":"10.1016","volume":"562","author":[{"given":"Bo","family":"Burla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeongah","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albina","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Piraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne K.","family":"Bendt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan\u2013Dirk","family":"Studt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat M.","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Torta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus R.","family":"Wenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre\u2013Alexandre","family":"Krayenbuehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2024.119833_b0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.cca.2024.119833_b0010","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2022.07.010","article-title":"An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease","volume":"137","author":"Germain","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.cca.2024.119833_b0015","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: Management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.cca.2024.119833_b0020","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1136\/heartjnl-2011-300364","article-title":"Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease Survey","volume":"97","author":"Elliott","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.cca.2024.119833_b0025","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.dld.2018.02.011","article-title":"Non-specific gastrointestinal features: Could it be Fabry disease?","volume":"50","author":"Hilz","year":"2018","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.cca.2024.119833_b0030","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12882-022-02805-8","article-title":"The prevalence of Fabry disease in a statewide chronic kidney disease cohort \u2013 Outcomes of the aCQuiRE (Ckd.Qld fabRy Epidemiology) study","volume":"23","author":"Mallett","year":"2022","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.cca.2024.119833_b0035","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.08.010","article-title":"Prevalence of Fabry Disease in Stroke Patients\u2014A Systematic Review and Meta-analysis","volume":"23","author":"Shi","year":"2014","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.cca.2024.119833_b0040","article-title":"Prevalence of Fabry disease-causing variants in the UK Biobank","author":"Gilchrist","year":"2022","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.cca.2024.119833_b0045","article-title":"Fabry disease: Mechanism and therapeutics strategies","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cca.2024.119833_b0050","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.cca.2010.06.023","article-title":"Quantification of \u03b1-galactosidase activity in intact leukocytes","volume":"411","author":"H\u00f6lzl","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2024.119833_b0055","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.jpeds.2009.07.003","article-title":"Guidelines to Diagnosis and Monitoring of Fabry Disease and Review of Treatment Experiences","volume":"155","author":"Martins","year":"2009","journal-title":"J. Pediatr."},{"key":"10.1016\/j.cca.2024.119833_b0060","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/gim.2016.55","article-title":"Is it Fabry disease?","volume":"18","author":"Schiffmann","year":"2016","journal-title":"Genet. Med."},{"key":"10.1016\/j.cca.2024.119833_b0065","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ymgme.2020.04.006","article-title":"A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females","volume":"130","author":"Stiles","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.cca.2024.119833_b0070","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.cca.2024.119833_b0075","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/gim.2018.31","article-title":"Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis","volume":"21","author":"Maruyama","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/j.cca.2024.119833_b0080","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","article-title":"Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease","volume":"123","author":"Nowak","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.cca.2024.119833_b0085","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/jmedgenet-2020-107338","article-title":"Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease","volume":"59","author":"Nowak","year":"2022","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.cca.2024.119833_b0090","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1515\/CCLM.2010.048","article-title":"Determination of globotriaosylceramide in plasma and urine by mass spectrometry","volume":"48","author":"Kr\u00fcger","year":"2010","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.cca.2024.119833_b0095","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jchromb.2004.02.032","article-title":"Globotriaosylceramide isoform profiles in human plasma by liquid chromatography\u2013tandem mass spectrometry","volume":"805","author":"Nelson","year":"2004","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.cca.2024.119833_b0100","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1373\/clinchem.2004.038323","article-title":"Liquid Chromatography-Tandem Mass Spectrometry Quantification of Globotriaosylceramide in Plasma for Long-Term Monitoring of Fabry Patients Treated with Enzyme Replacement Therapy","volume":"51","author":"Roddy","year":"2005","journal-title":"Clin. Chem."},{"key":"10.1016\/j.cca.2024.119833_b0105","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1194\/jlr.RA120000909","article-title":"Assessing the role of glycosphingolipids in the phenotype severity of Fabry disease mouse model","volume":"61","author":"Jabbarzadeh-Tabrizi","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2024.119833_b0110","article-title":"Distinctive accumulation of globotriaosylceramide and globotriaosylsphingosine in a mouse model of classic Fabry disease","volume":"34","author":"Taguchi","year":"2023","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.cca.2024.119833_b0115","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO;2-T","article-title":"Profile of endothelial and leukocyte activation in fabry patients","volume":"47","author":"DeGraba","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.cca.2024.119833_b0120","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/ajh.2830220110","article-title":"Activation of platelet function in Fabry\u2019s disease","volume":"22","author":"Igarashi","year":"1986","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.cca.2024.119833_b0125","first-page":"gfp263","article-title":"Plasma markers of coagulation and endothelial activation in Fabry disease: impact of renal impairment","author":"Vedder","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.cca.2024.119833_b0130","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3390\/metabo12040333","article-title":"Lipidomics in Understanding Pathophysiology and Pharmacologic Effects in Inflammatory Diseases: Considerations for Drug Development","volume":"12","author":"Ahluwalia","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.cca.2024.119833_b0135","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s12890-017-0513-4","article-title":"Identification of the lipid biomarkers from plasma in idiopathic pulmonary fibrosis by Lipidomics","volume":"17","author":"Yan","year":"2017","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.cca.2024.119833_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2023.100378","article-title":"Ex vivo instability of lipids in whole blood: preanalytical recommendations for clinical lipidomics studies","volume":"64","author":"Wang","year":"2023","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2024.119833_b0145","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/j.ajkd.2021.08.003","article-title":"A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease","volume":"79","author":"Delgado","year":"2022","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.cca.2024.119833_b0150","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1182\/blood-2012-04-416594","article-title":"The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways","volume":"120","author":"Burkhart","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.cca.2024.119833_b0155","first-page":"17","article-title":"CTAD as a universal anticoagulant","volume":"25","author":"Yokota","year":"2003","journal-title":"J. Anal. Methods Chem."},{"key":"10.1016\/j.cca.2024.119833_b0160","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3390\/metabo5020389","article-title":"An efficient single phase method for the extraction of plasma lipids","volume":"5","author":"Alshehry","year":"2015","journal-title":"Metabolites"},{"key":"10.1016\/j.cca.2024.119833_b0165","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.cca.2020.10.007","article-title":"Combined analysis of plasma or serum glucosylsphingosine and globotriaosylsphingosine by UPLC-MS\/MS","volume":"511","author":"Beasley","year":"2020","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cca.2024.119833_b0170","doi-asserted-by":"crossref","first-page":"13382","DOI":"10.1021\/acs.analchem.7b03609","article-title":"Separation and Analysis of Lactosylceramide, Galabiosylceramide, and Globotriaosylceramide by LC-MS\/MS in Urine of Fabry Disease Patients","volume":"89","author":"Boutin","year":"2017","journal-title":"Anal. Chem."},{"key":"10.1016\/j.cca.2024.119833_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109250","article-title":"A reference map of sphingolipids in murine tissues","volume":"35","author":"Muralidharan","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.cca.2024.119833_b0180","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4939-7592-1_11","article-title":"Sphingolipid Analysis in Clinical Research","author":"Burla","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.cca.2024.119833_b0185","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1021\/ac4039652","article-title":"Lipidomic \u201cdeep profiling\u201d: an enhanced workflow to reveal new molecular species of signaling lipids","volume":"86","author":"Narayanaswamy","year":"2014","journal-title":"Anal Chem"},{"key":"10.1016\/j.cca.2024.119833_b0190","first-page":"71","article-title":"High-Throughput Plasma Lipidomics: Detailed Mapping of the Associations with Cardiometabolic Risk Factors, Cell","volume":"26","author":"Huynh","year":"2019","journal-title":"Chem. Biol."},{"key":"10.1016\/j.cca.2024.119833_b0195","unstructured":"Baker Heart and Diabetes Institute Metabolomics Laboratory Portal, (2023). https:\/\/metabolomics.baker.edu.au\/method\/lipids."},{"key":"10.1016\/j.cca.2024.119833_b0200","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1021\/acs.analchem.0c04565","article-title":"LICAR: An Application for Isotopic Correction of Targeted Lipidomic Data Acquired with Class-Based Chromatographic Separations Using Multiple Reaction Monitoring","volume":"93","author":"Gao","year":"2021","journal-title":"Anal. Chem."},{"key":"10.1016\/j.cca.2024.119833_b0205","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/nprot.2011.335","article-title":"Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry","volume":"6","author":"Dunn","year":"2011","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.cca.2024.119833_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.aca.2023.341274","article-title":"Scrutinizing different ionization responses of polar lipids in a reversed-phase gradient by implementing a counter-gradient","volume":"1265","author":"Hildebrand","year":"2023","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.cca.2024.119833_b0215","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1194\/jlr.S120001025","article-title":"Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures","volume":"61","author":"Liebisch","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2024.119833_b0220","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/s42255-022-00628-3","article-title":"Introducing the Lipidomics Minimal Reporting Checklist","volume":"4","author":"McDonald","year":"2022","journal-title":"Nat. Metab."},{"key":"10.1016\/j.cca.2024.119833_b0225","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: A practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. r. Stat. Soc. Ser. B Methodol."},{"key":"10.1016\/j.cca.2024.119833_b0230","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/1467-9868.00346","article-title":"A direct approach to false discovery rates","volume":"64","author":"Storey","year":"2002","journal-title":"J. R. Stat. Soc. Ser. B Stat. Methodol."},{"key":"10.1016\/j.cca.2024.119833_b0235","doi-asserted-by":"crossref","unstructured":"C. Ahlmann-Eltze, I. Patil, ggsignif: R Package for Displaying Significance Brackets for \u201cggplot2,\u201d (2021). Doi: 10.31234\/osf.io\/7awm6.","DOI":"10.31234\/osf.io\/7awm6"},{"key":"10.1016\/j.cca.2024.119833_b0240","unstructured":"R. Iannone, J. Cheng, B. Schloerke, E. Hughes, A. Lauer, J. Seo, gt: Easily create presentation-ready display tables, 2023. https:\/\/CRAN.R-project.org\/package=gt."},{"key":"10.1016\/j.cca.2024.119833_b0245","unstructured":"A. Kassambara, ggpubr: \u201cggplot2\u201d based publication ready plots, 2023. https:\/\/CRAN.R-project.org\/package=ggpubr."},{"key":"10.1016\/j.cca.2024.119833_b0250","unstructured":"T.L. Pedersen, patchwork: The composer of plots, 2022. https:\/\/CRAN.R-project.org\/package=patchwork."},{"key":"10.1016\/j.cca.2024.119833_b0255","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the Tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J. Open Source Softw."},{"key":"10.1016\/j.cca.2024.119833_b0260","unstructured":"J.D. Storey, A.J. Bass, A. Dabney, D. Robinson, qvalue: Q-value estimation for false discovery rate control, 2023. Doi: 10.18129\/B9.bioc.qvalue."},{"key":"10.1016\/j.cca.2024.119833_b0265","doi-asserted-by":"crossref","unstructured":"D.P. Germain, E. Brand, A. Burlina, F. Cecchi, S.C. Garman, J. Kempf, D.A. Laney, A. Linhart, L. Marodi, K. Nicholls, A. Ortiz, F. Pieruzzi, S.P. Shankar, S. Waldek, C. Wanner, A. Jovanovic, Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study, Mol Genet Genomic Med (2018). Doi: 10.1002\/mgg3.389.","DOI":"10.1002\/mgg3.389"},{"key":"10.1016\/j.cca.2024.119833_b0270","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2169\/internalmedicine.0959-18","article-title":"Clinical Diversity in Patients with Anderson-fabry Disease with the R301Q Mutation","volume":"58","author":"Yamamoto","year":"2019","journal-title":"Intern. Med."},{"key":"10.1016\/j.cca.2024.119833_b0275","first-page":"94","article-title":"Echocardiography for clarification of arterial hypertension","volume":"20","author":"Dichtl","year":"2016","journal-title":"J. F\u00fcr Hyperton. - Austrian J. Hypertens."},{"key":"10.1016\/j.cca.2024.119833_b0280","first-page":"766","article-title":"Sphingosine 1-phosphate is a key metabolite linking sphingolipids to glycerophospholipids","volume":"1841","author":"Kihara","year":"2014","journal-title":"Biochim. Biophys. Acta BBA - Mol. Cell Biol Lipids"},{"key":"10.1016\/j.cca.2024.119833_b0285","doi-asserted-by":"crossref","first-page":"13397","DOI":"10.1074\/jbc.M112.428185","article-title":"Myristate-derived d16:0 Sphingolipids Constitute a Cardiac Sphingolipid Pool with Distinct Synthetic Routes and Functional Properties","volume":"288","author":"Russo","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cca.2024.119833_b0290","article-title":"Ceramides and Ceramide Scores: Clinical Applications for Cardiometabolic Risk Stratification","volume":"11","author":"Hilvo","year":"2020","journal-title":"Front Endocrinol Lausanne"},{"key":"10.1016\/j.cca.2024.119833_b0295","doi-asserted-by":"crossref","first-page":"9039","DOI":"10.1021\/ac401542k","article-title":"A Metabolomic Study To Identify New Globotriaosylceramide-Related Biomarkers in the Plasma of Fabry Disease Patients","volume":"85","author":"Manwaring","year":"2013","journal-title":"Anal. Chem."},{"key":"10.1016\/j.cca.2024.119833_b0300","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","article-title":"Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy","volume":"1812","author":"van Breemen","year":"2011","journal-title":"Biochim. Biophys. Acta BBA - Mol. Basis Dis."},{"key":"10.1016\/j.cca.2024.119833_b0305","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/0005-2760(66)90012-9","article-title":"Neutral glycolipids of human kidney isolation, identification, and fatty acid composition","volume":"116","author":"M\u00e5rtensson","year":"1966","journal-title":"Biochim. Biophys. Acta BBA - Lipids Lipid Metab."},{"key":"10.1016\/j.cca.2024.119833_b0310","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0022-2275(20)42667-7","article-title":"Concentrations of glycosyl ceramides in plasma and red cells in Fabry\u2019s disease, a glycolipid lipidosis","volume":"10","author":"Vance","year":"1969","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.cca.2024.119833_b0315","doi-asserted-by":"crossref","first-page":"10177","DOI":"10.3390\/ijms241210177","article-title":"New Perspectives in Dried Blood Spot Biomarkers for Lysosomal Storage Diseases","volume":"24","author":"Spiewak","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cca.2024.119833_b0320","doi-asserted-by":"crossref","first-page":"e21818","DOI":"10.1096\/fj.202001727RR","article-title":"Platelet and myeloid cell phenotypes in a rat model of Fabry disease","volume":"35","author":"Kanack","year":"2021","journal-title":"FASEB J"},{"key":"10.1016\/j.cca.2024.119833_b0325","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99171","article-title":"Neuropathic pain in a Fabry disease rat model","volume":"3","author":"Miller","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.cca.2024.119833_b0330","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1128\/IAI.66.9.4355-4366.1998","article-title":"Shiga Toxin Binds Human Platelets via Globotriaosylceramide (Pk Antigen) and a Novel Platelet Glycosphingolipid","volume":"66","author":"Cooling","year":"1998","journal-title":"Infect. Immun."},{"key":"10.1016\/j.cca.2024.119833_b0335","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/hdy.1953.7","article-title":"The variation in strength of the human blood group P","volume":"7","author":"Fisher","year":"1953","journal-title":"Heredity"},{"key":"10.1016\/j.cca.2024.119833_b0340","doi-asserted-by":"crossref","first-page":"99","DOI":"10.21307\/immunohematology-2020-048","article-title":"The P1PK blood group system: revisited and resolved","volume":"36","author":"Stenfelt","year":"2020","journal-title":"Immunohematology"},{"key":"10.1016\/j.cca.2024.119833_b0345","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2010-08-301333","article-title":"Identification of a novel A4GALT exon reveals the genetic basis of the P1\/P2 histo-blood groups","volume":"117","author":"Thuresson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.cca.2024.119833_b0350","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.926220","article-title":"Immunolipidomics Reveals a Globoside Network During the Resolution of Pro-Inflammatory Response in Human Macrophages","volume":"13","author":"Muralidharan","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2024.119833_b0355","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.neuron.2017.01.018","article-title":"The complicated relationship between Gaucher disease and Parkinsonism: Insights from a rare disease","volume":"93","author":"Aflaki","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.cca.2024.119833_b0360","doi-asserted-by":"crossref","first-page":"e0172348","DOI":"10.1371\/journal.pone.0172348","article-title":"Elevated GM3 plasma concentration in idiopathic Parkinson\u2019s disease: A lipidomic analysis","volume":"12","author":"Chan","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.cca.2024.119833_b0365","first-page":"141","article-title":"Parkinson\u2019s Disease and Fabry Disease: Clinical, Biochemical and Neuroimaging Analysis of Three Pedigrees","volume":"10","author":"Gago","year":"2020","journal-title":"J Park. Dis"},{"key":"10.1016\/j.cca.2024.119833_b0370","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ymgmr.2017.10.013","article-title":"Parkinson\u2019s disease prevalence in Fabry disease: A survey study","volume":"14","author":"Wise","year":"2018","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.cca.2024.119833_b0375","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehp387","article-title":"Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease","volume":"31","author":"Brakch","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cca.2024.119833_b0380","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19051390","article-title":"Preanalytical Biases in the Measurement of Human Blood Sphingolipids","volume":"19","author":"Brunkhorst","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.cca.2024.119833_b0385","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1096\/fj.06-7433com","article-title":"Erythrocytes store and release sphingosine 1-phosphate in blood","volume":"21","author":"H\u00e4nel","year":"2007","journal-title":"FASEB J."},{"key":"10.1016\/j.cca.2024.119833_b0390","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/jcb.22507","article-title":"Erythrocytes serve as a reservoir for cellular and extracellular sphingosine 1-phosphate","volume":"109","author":"Bode","year":"2010","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.cca.2024.119833_b0395","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature24053","article-title":"Mfsd2b is essential for the sphingosine-1-phosphate export in erythrocytes and platelets","volume":"550","author":"Vu","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.cca.2024.119833_b0400","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1111\/j.1523-1755.2005.00294.x","article-title":"Anemia is a new complication in Fabry disease: data from the Fabry Outcome Survey","volume":"67","author":"Kleinert","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.cca.2024.119833_b0405","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1042\/CS20110236","article-title":"Plasma levels of sphingosine 1-phosphate are strongly correlated with haematocrit, but variably restored by red blood cell transfusions","volume":"121","author":"Selim","year":"2011","journal-title":"Clin. Sci."},{"key":"10.1016\/j.cca.2024.119833_b0410","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nchembio.392","article-title":"An update on sphingosine-1-phosphate and other sphingolipid mediators","volume":"6","author":"Fyrst","year":"2010","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.cca.2024.119833_b0415","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/STROKEAHA.114.006283","article-title":"Cerebrovascular Involvement in Fabry Disease","volume":"46","author":"Kolodny","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.cca.2024.119833_b0420","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3389\/fneur.2020.00985","article-title":"Serum Sphingosine 1-Phosphate (S1P): A Novel Diagnostic Biomarker in Early Acute Ischemic Stroke","volume":"11","author":"Liu","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.cca.2024.119833_b0425","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1161\/STROKEAHA.120.033414","article-title":"Serum Sphingosine-1-Phosphate Levels Are Associated With Severity and Outcome in Patients With Cerebral Ischemia","volume":"52","author":"Schwedhelm","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.cca.2024.119833_b0430","doi-asserted-by":"crossref","unstructured":"J.-J. Aguilera-Correa, P. Madrazo-Clemente, M. del C. Mart\u00ednez-Cuesta, C. Pel\u00e1ez, A. Ortiz, M.D. S\u00e1nchez-Ni\u00f1o, J. Esteban, T. Requena, Lyso-Gb3 modulates the gut microbiota and decreases butyrate production, Sci. Rep. 9 (2019) 12010. Doi: 10.1038\/s41598-019-48426-4.","DOI":"10.1038\/s41598-019-48426-4"},{"key":"10.1016\/j.cca.2024.119833_b0435","doi-asserted-by":"crossref","first-page":"2027852","DOI":"10.1080\/19490976.2022.2027852","article-title":"Fabry disease \u2013 a multisystemic disease with gastrointestinal manifestations","volume":"14","author":"Lenders","year":"2022","journal-title":"Gut Microbes"},{"key":"10.1016\/j.cca.2024.119833_b0440","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2337\/db23-0052","article-title":"Ceramides as Risk Markers for Future Cardiovascular Events and All-Cause Mortality in Long-standing Type 1 Diabetes","volume":"72","author":"Wretlind","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.cca.2024.119833_b0445","doi-asserted-by":"crossref","unstructured":"A.S. Havulinna, M. Sysi-Aho, M. Hilvo, D. Kauhanen, R. Hurme, K. Ekroos, V. Salomaa, R. Laaksonen, Circulating Ceramides Predict Cardiovascular Outcomes in the Population-Based FINRISK 2002 Cohort, Arterioscler. Thromb. Vasc. Biol. 36 (2016) 2424\u20132430. Doi: 10.1161\/ATVBAHA.116.307497.","DOI":"10.1161\/ATVBAHA.116.307497"},{"key":"10.1016\/j.cca.2024.119833_b0450","doi-asserted-by":"crossref","unstructured":"L.R. Peterson, V. Xanthakis, M.S. Duncan, S. Gross, N. Friedrich, H. V\u00f6lzke, S.B. Felix, H. Jiang, R. Sidhu, M. Nauck, X. Jiang, D.S. Ory, M. D\u00f6rr, R.S. Vasan, J.E. Schaffer, Ceramide Remodeling and Risk of Cardiovascular Events and Mortality, J. Am. Heart Assoc. 7 (n.d.) e007931. Doi: 10.1161\/JAHA.117.007931.","DOI":"10.1161\/JAHA.117.007931"},{"key":"10.1016\/j.cca.2024.119833_b0455","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jacl.2022.02.001","article-title":"CERT2 ceramide- and phospholipid-based risk score and major adverse cardiovascular events: A systematic review and meta-analysis","volume":"16","author":"Papazoglou","year":"2022","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.cca.2024.119833_b0460","doi-asserted-by":"crossref","first-page":"e010171","DOI":"10.1161\/CIRCIMAGING.119.010171","article-title":"Myocardial Edema, Myocyte Injury, and Disease Severity in Fabry Disease","volume":"13","author":"Augusto","year":"2020","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"10.1016\/j.cca.2024.119833_b0465","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijcard.2017.09.027","article-title":"Impact of cardio-renal syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up","volume":"249","author":"Siegenthaler","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cca.2024.119833_b0470","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1182\/bloodadvances.2021006687","article-title":"CPT2 K79 acetylation regulates platelet life span","volume":"6","author":"Fan","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.cca.2024.119833_b0475","doi-asserted-by":"crossref","first-page":"e280","DOI":"10.1038\/cddis.2012.17","article-title":"C16 ceramide is crucial for triacylglycerol-induced apoptosis in macrophages","volume":"3","author":"Aflaki","year":"2012","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.cca.2024.119833_b0480","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1038\/s41467-018-06650-y","article-title":"C16-ceramide is a natural regulatory ligand of p53 in cellular stress response","volume":"9","author":"Fekry","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cca.2024.119833_b0485","doi-asserted-by":"crossref","first-page":"7485","DOI":"10.1073\/pnas.1804266115","article-title":"Traceless synthesis of ceramides in living cells reveals saturation-dependent apoptotic effects","volume":"115","author":"Rudd","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.cca.2024.119833_b0490","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/eurheartj\/ehx146","article-title":"Regulation of oxidized platelet lipidome: implications for coronary artery disease","volume":"38","author":"Chatterjee","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.cca.2024.119833_b0495","doi-asserted-by":"crossref","first-page":"e106272","DOI":"10.15252\/embj.2020106272","article-title":"Cellular stress promotes NOD1\/2-dependent inflammation via the endogenous metabolite sphingosine-1-phosphate","volume":"40","author":"Pei","year":"2021","journal-title":"EMBO J."},{"key":"10.1016\/j.cca.2024.119833_b0500","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3390\/jpm11090898","article-title":"Parsing Fabry Disease Metabolic Plasticity Using Metabolomics","volume":"11","author":"Ducatez","year":"2021","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.cca.2024.119833_b0505","doi-asserted-by":"crossref","first-page":"e3000870","DOI":"10.1371\/journal.pbio.3000870","article-title":"High-coverage plasma lipidomics reveals novel sex-specific lipidomic fingerprints of age and BMI: Evidence from two large population cohort studies","volume":"18","author":"Beyene","year":"2020","journal-title":"PLoS Biol."},{"key":"10.1016\/j.cca.2024.119833_b0510","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1194\/jlr.D008532","article-title":"Blood sphingolipidomics in healthy humans: impact of sample collection methodology","volume":"51","author":"Hammad","year":"2010","journal-title":"J. Lipid Res."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898124020850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898124020850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T03:15:38Z","timestamp":1732331738000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898124020850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":102,"alternative-id":["S0009898124020850"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2024.119833","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma and platelet lipidome changes in Fabry disease","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2024.119833","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"119833"}}